Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00128102
First received: August 5, 2005
Last updated: April 17, 2015
Last verified: April 2015